Form 4: Bioxytran Director Alan Hoberman Reports Acquisition and Disposal of Common Stock
SEC Form 4 Filing
Director Alan Hoberman reports acquiring and disposing of Bioxytran, Inc. (BIXT) common stock on April 19, 2024.
Summary
- On April 19, 2024, Alan Hoberman, a director of Bioxytran, Inc. (BIXT), engaged in transactions involving the company's common stock.
- Hoberman acquired 70,423 shares of common stock at a price of $0.142 per share.
- Following the reported transactions, Hoberman beneficially owns 1,009,422 shares of Bioxytran common stock.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock transactions by a company director. The sentiment is neutral as it simply reports facts without indicating positive or negative implications for the company.
Industry Context
Form 4 filings are standard disclosures required by the SEC when corporate insiders (officers, directors, and 10% owners) buy or sell their company's stock. These filings provide transparency to the market regarding insider transactions.
Stakeholder Impact
- The filing provides transparency to shareholders regarding insider transactions, allowing them to assess the actions of company leadership.
Key Dates
| Date | Description |
|---|---|
| 01/19/2024 | Date of signature for the report. |
| 04/19/2024 | Date of transaction involving Bioxytran common stock. |
Keywords
Form 4, Bioxytran, BIXT, Alan Hoberman, Director, Stock Transaction, Beneficial Ownership, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.